Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2010-7-5
pubmed:abstractText
We sought to compare survival and toxicity between paclitaxel/carboplatin (TC) and doxorubicin/cisplatin (AP) for concurrent chemoradiation (CCR) in intermediate- or high-risk endometrioid endometrial cancer.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
1341-8076
pubmed:author
pubmed:issnType
Print
pubmed:volume
36
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
598-604
pubmed:meshHeading
pubmed-meshheading:20598043-Adult, pubmed-meshheading:20598043-Aged, pubmed-meshheading:20598043-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:20598043-Carboplatin, pubmed-meshheading:20598043-Carcinoma, Endometrioid, pubmed-meshheading:20598043-Cisplatin, pubmed-meshheading:20598043-Databases, Factual, pubmed-meshheading:20598043-Disease-Free Survival, pubmed-meshheading:20598043-Doxorubicin, pubmed-meshheading:20598043-Endometrial Neoplasms, pubmed-meshheading:20598043-Female, pubmed-meshheading:20598043-Humans, pubmed-meshheading:20598043-Middle Aged, pubmed-meshheading:20598043-Neoplasm Staging, pubmed-meshheading:20598043-Paclitaxel, pubmed-meshheading:20598043-Radiotherapy, Adjuvant, pubmed-meshheading:20598043-Retrospective Studies, pubmed-meshheading:20598043-Statistics, Nonparametric, pubmed-meshheading:20598043-Treatment Outcome
pubmed:year
2010
pubmed:articleTitle
Comparison of the efficacy between paclitaxel/carboplatin and doxorubicin/cisplatin for concurrent chemoradiation in intermediate- or high-risk endometrioid endometrial cancer: a single institution experience.
pubmed:affiliation
Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea.
pubmed:publicationType
Journal Article, Comparative Study, Research Support, Non-U.S. Gov't